Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma

After bursting out of the gate early in the COVID-19 vaccine push, Novavax quickly fell behind the pack. Manufacturing challenges and other delays slowed clinical progress, and Novavax didn’t score an FDA emergency use authorization until July 2022, more than a year and a half after its mRNA rivals.